KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInterest Coverage RatioInvested CapitalMarket CapitalizationNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on SalesTimes Interest Earned

TherapeuticsMD (TXMD) FCF Margin: 2010-2025

Historic FCF Margin for TherapeuticsMD (TXMD) over the last 15 years, with Sep 2025 value amounting to 127.42%.

  • TherapeuticsMD's FCF Margin rose 14040.00% to 127.42% in Q3 2025 from the same period last year, while for Sep 2025 it was 74.96%, marking a year-over-year increase of 31350.00%. This contributed to the annual value of 66.44% for FY2024, which is 183917.00% up from last year.
  • According to the latest figures from Q3 2025, TherapeuticsMD's FCF Margin is 127.42%, which was up 218.39% from 40.02% recorded in Q2 2025.
  • In the past 5 years, TherapeuticsMD's FCF Margin ranged from a high of 5,004.52% in Q3 2022 and a low of -11,373.58% during Q3 2023.
  • For the 3-year period, TherapeuticsMD's FCF Margin averaged around -1,304.25%, with its median value being -12.98% (2024).
  • Per our database at Business Quant, TherapeuticsMD's FCF Margin plummeted by 1,637,810bps in 2023 and then skyrocketed by 1,136,061bps in 2024.
  • Quarterly analysis of 5 years shows TherapeuticsMD's FCF Margin stood at 257.00% in 2021, then crashed by 21,290bps to 44.10% in 2022, then crashed by 103,215bps to -988.05% in 2023, then soared by 99,060bps to 2.55% in 2024, then spiked by 14,040bps to 127.42% in 2025.
  • Its last three reported values are 127.42% in Q3 2025, 40.02% for Q2 2025, and 177.86% during Q1 2025.